Impact of Daily Oral Cannabis Doses in Patients With Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will enroll patients with cancer and participants will be randomized to receive one dose of cannabis for approximately 4 months. There is a 3/4 (or 75%) chance that a participant will receive an active cannabis dose in the study. There is a 1/4 (or 25% chance) that a participant will receive a placebo dose (meaning a blank dose/no cannabis/no active drug). The goals of this study are to determine 1) the safety and tolerability of cannabis in individuals with cancer and 2) if cannabis can help with the side effects of cancer and cancer treatment - including nausea and vomiting, appetite, pain, sleep, and quality of life.
Sponsor: Shanna Babalonis, PhD
You may not qualify if…
- ✕ History of hypersensitivity to cannabis or cannabinoids
- ✕ Current, regular use of cannabis/marijuana or THC-containing medications (dronabinol, nabilone) or cannabidiol (Epidiolex) or over-the-counter (OTC) CBD oil.
- ✕ Concomitant use of checkpoint inhibitors (e.g., anti-PD1, PDL1, CTLA4) or other drugs for which an cannabinoid interaction may occur.
- ✕ Current use of investigational agents, \<3 months after the use of investigational agents
- ✕ Cardiac conditions contraindicated for cannabis use
- ✕ Diagnosis of HPV-related cancer, as there is some evidence that cannabis is contraindicated
- ✕ Allergy to any constituent/ingredient contained in the edible dose
- ✕ Psychiatric illness/social situations that would limit compliance with study requirements (e.g., bipolar disorder, psychosis, severe depression/anxiety).
Where it's recruiting
Lexington
Source: ClinicalTrials.gov · NCT06601218 · last updated 2026-07-15